Diamond Hill Capital's ABT Position Overview
Diamond Hill Capital (via Diamond Hill Capital Management INC) currently holds 5.17 M shares of Abbott Laboratories (ABT) worth $647.69 M, representing 3.32% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Diamond Hill Capital has maintained a long-term strategic position in ABT, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2014, adding 2.9 M shares. Largest reduction occurred in Q4 2018, reducing 1.28 M shares.
Analysis based on 13F filings available since 2013 Q2
Diamond Hill Capital's Abbott Laboratories (ABT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Abbott Laboratories (ABT) Trades by Diamond Hill Capital
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -434,070 | Reduce 7.75% | 5.17 M | $125.29 |
| Q3 2025 | -309,225 | Reduce 5.23% | 5.6 M | $133.94 |
| Q2 2025 | -160,957 | Reduce 2.65% | 5.91 M | $136.01 |
| Q1 2025 | -477,768 | Reduce 7.29% | 6.07 M | $132.65 |
| Q4 2024 | -132,053 | Reduce 1.98% | 6.55 M | $113.11 |
| Q3 2024 | +524,683 | Add 8.52% | 6.68 M | $114.01 |
| Q2 2024 | +1.01 M | Add 19.72% | 6.16 M | $103.91 |
| Q1 2024 | -67,724 | Reduce 1.30% | 5.14 M | $113.66 |
| Q4 2023 | +148,126 | Add 2.93% | 5.21 M | $110.07 |
| Q3 2023 | -12,201 | Reduce 0.24% | 5.06 M | $96.85 |
| Q2 2023 | -145,124 | Reduce 2.78% | 5.08 M | $109.02 |
| Q1 2023 | -93,698 | Reduce 1.76% | 5.22 M | $101.26 |
| Q4 2022 | -415,097 | Reduce 7.24% | 5.32 M | $109.79 |
| Q3 2022 | -156,517 | Reduce 2.66% | 5.73 M | $96.76 |
| Q2 2022 | -213,246 | Reduce 3.50% | 5.89 M | $108.65 |
| Q1 2022 | +50,118 | Add 0.83% | 6.1 M | $118.36 |
| Q4 2021 | -151,993 | Reduce 2.45% | 6.05 M | $140.74 |
| Q3 2021 | -32,063 | Reduce 0.51% | 6.2 M | $118.13 |
| Q2 2021 | +169,608 | Add 2.80% | 6.23 M | $115.93 |
| Q1 2021 | +176,198 | Add 2.99% | 6.06 M | $119.84 |
| Q4 2020 | +285,195 | Add 5.09% | 5.89 M | $109.49 |
| Q3 2020 | -732,477 | Reduce 11.56% | 5.6 M | $108.83 |
| Q2 2020 | +20,975 | Add 0.33% | 6.34 M | $91.43 |
| Q1 2020 | -68,769 | Reduce 1.08% | 6.31 M | $78.91 |
| Q4 2019 | -28,992 | Reduce 0.45% | 6.38 M | $86.86 |
| Q3 2019 | -101,260 | Reduce 1.55% | 6.41 M | $83.67 |
| Q2 2019 | -461,641 | Reduce 6.62% | 6.51 M | $84.10 |
| Q1 2019 | -650,084 | Reduce 8.53% | 6.98 M | $79.94 |
| Q4 2018 | -1.28 M | Reduce 14.38% | 7.63 M | $72.33 |
| Q3 2018 | -1.21 M | Reduce 11.97% | 8.91 M | $73.36 |
| Q2 2018 | -349,757 | Reduce 3.34% | 10.12 M | $60.99 |
| Q1 2018 | -93,054 | Reduce 0.88% | 10.47 M | $59.92 |
| Q4 2017 | -480,031 | Reduce 4.35% | 10.56 M | $57.07 |
| Q3 2017 | -924,314 | Reduce 7.73% | 11.04 M | $53.36 |
| Q2 2017 | -327,306 | Reduce 2.66% | 11.96 M | $48.61 |
| Q1 2017 | -196,624 | Reduce 1.57% | 12.29 M | $44.41 |
| Q4 2016 | +612,230 | Add 5.16% | 12.49 M | $38.41 |
| Q3 2016 | -92,889 | Reduce 0.78% | 11.88 M | $42.29 |
| Q2 2016 | +1.77 M | Add 17.36% | 11.97 M | $39.31 |
| Q1 2016 | +1.58 M | Add 18.28% | 10.2 M | $41.83 |
| Q4 2015 | +236,352 | Add 2.82% | 8.62 M | $44.91 |
| Q3 2015 | +322,728 | Add 4.00% | 8.39 M | $40.22 |
| Q2 2015 | -44,203 | Reduce 0.55% | 8.06 M | $49.08 |
| Q1 2015 | +36,171 | Add 0.45% | 8.11 M | $46.33 |
| Q4 2014 | +446,334 | Add 5.85% | 8.07 M | $45.02 |
| Q3 2014 | +1.2 M | Add 18.72% | 7.62 M | $41.59 |
| Q2 2014 | +437,570 | Add 7.31% | 6.42 M | $40.90 |
| Q1 2014 | +2.9 M | Add 93.78% | 5.98 M | $38.51 |
| Q4 2013 | +6,197 | Add 0.20% | 3.09 M | $38.33 |
| Q3 2013 | +204,427 | Add 7.10% | 3.08 M | $33.19 |
| Q2 2013 | +2.88 M | Add 0.00% | 2.88 M | $34.88 |
Diamond Hill Capital's Abbott Laboratories Investment FAQs
Diamond Hill Capital first purchased Abbott Laboratories (ABT) in Q2 2013, acquiring 2,877,757 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Diamond Hill Capital has held Abbott Laboratories (ABT) for 51 quarters since Q2 2013.
Diamond Hill Capital's largest addition to Abbott Laboratories (ABT) was in Q1 2014, adding 5,984,714 shares worth $230.47 M.
According to the latest 13F filing for Q4 2025, Diamond Hill Capital's firm, Diamond Hill Capital Management INC, owns 5,169,513 shares of Abbott Laboratories (ABT), valued at approximately $647.69 M.
As of the Q4 2025 filing, Abbott Laboratories (ABT) represents approximately 3.32% of Diamond Hill Capital's publicly disclosed stock portfolio, making it one of their key holdings.
Diamond Hill Capital's peak holding in Abbott Laboratories (ABT) was 12,488,011 shares, as reported at the end of Q4 2016.